Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
US-Japan collaboration for liquid biopsy screening in lung cancer
2+ day, 13+ hour ago (134+ words) BioSpectrum Asia US-Japan collaboration for liquid biopsy screening in lung cancer August 21, 2026 | Friday | News oncoReveal® Essential+ validated at LSI Medience for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026 US-based Pillar Biosciences, Inc., LC-SCRUM-Asia…...
Taiwan's Astron Medtech receives Presidential Award, accelerates US commercial expansion
2+ day, 13+ hour ago (115+ words) August 21, 2026 | Friday | News Aztron Medtech Corporation, a US-based orthopaedic device company, has announced that its Taiwan subsidiary, Astron Medtech, has received the Presidential Award, the highest honor presented through Taiwan's National Development Council (NDC) Startup Programme, together with a NT…...
Genentech injects $750 M in new device fill-finish manufacturing facility in US
2+ day, 13+ hour ago (180+ words) August 21, 2026 | Friday | News Genentech, a member of the Roche Group, has announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon in the US. The investment will bring new end-to-end…...
Telix advances radiopharmaceutical pipeline as H1 revenue reaches $477 million
2+ day, 16+ hour ago (248+ words) August 21, 2026 | Friday | News Telix Pharmaceuticals has reported continued progress across its radiopharmaceutical imaging and therapeutic pipeline during the first half of 2026, alongside group revenue of $477 million. Telix’s precision medicine segment recorded 27% year-on-year revenue growth, supported by increasing volumes of its…...
Korea's Crescom inks MoU with UKM Medical College in Malaysia for bone age analysis
2+ day, 13+ hour ago (139+ words) August 21, 2026 | Friday | News South Korea-based Crescom, a company specialising in musculoskeletal medical artificial intelligence (AI), has signed a joint research agreement with the Faculty of Medicine at the National University of Malaysia (UKM) to verify the accuracy of its bone…...
Brii Biosciences advances mRNA cancer vaccine into clinical evaluation for liver cancer
2+ day, 16+ hour ago (244+ words) August 21, 2026 | Friday | News The first participant was dosed on 12 August 2026 in a study being conducted at the Cancer Hospital of the Chinese Academy of Medical Sciences. BRII-5395 is being evaluated as part of a combination immunotherapy approach together with an…...
GSK’s Blenrep combinations approved in Singapore for relapsed or refractory multiple myeloma
2+ day, 16+ hour ago (257+ words) August 21, 2026 | Friday | News GSK Singapore has received Health Sciences Authority approval for Blenrep, or belantamab mafodotin, in two combination regimens for adults with relapsed or refractory multiple myeloma. Blenrep in combination with bortezomib and dexamethasone has been approved for patients…...
Indian societies issue first joint consensus on personalised obesity management
2+ day, 17+ hour ago (537+ words) August 21, 2026 | Friday | News The Obesity and Metabolic Surgery Society of India and the Endocrine Society of India have issued their first joint consensus on obesity management, calling for the condition to be treated as a chronic disease rather than a…...
Ono Pharma's Opdivo intravenous infusion wins additional approval in Taiwan
3+ day, 20+ hour ago (283+ words) BioSpectrum Asia Ono Pharma's Opdivo intravenous infusion wins additional approval in Taiwan August 20, 2026 | Thursday | News Approval is based on results from the CheckMate-77T trial Japan-based Ono Pharmaceutical has announced that Ono Pharma Taiwan, a Taiwanese subsidiary of Ono, has received…...
Japan's Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351
3+ day, 20+ hour ago (90+ words) August 20, 2026 | Thursday | News Japan-based Chugai Pharmaceutical has signed an exclusive license agreement with British pharma firm GlaxoSmithKline (GSK) for the anti-dengue virus antibody “AID351”. This agreement builds on a joint development initiative for an anti-dengue virus antibody aimed at overcoming dengue…...